A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) - Trial NCT06137183
Access comprehensive clinical trial information for NCT06137183 through Pure Global AI's free database. This Phase 2 trial is sponsored by Genentech, Inc. and is currently Not yet recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 210 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Genentech, Inc.
Timeline & Enrollment
Phase 2
Jan 15, 2024
May 01, 2027
Primary Outcome
Proportion of Participants with Clinical Remission
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of
 vixarelimab compared with placebo in participants with moderate to severe UC who have
 demonstrated inadequate response to, loss of response to, or intolerance to prior
 conventional or advanced therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06137183
Non-Device Trial